회사 개요
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform designed to connect consumers with licensed healthcare professionals across the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and international markets. This operational scope places the entity firmly within the Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, which implies a focus on the production and distribution of specialized pharmaceutical products and generic medications rather than traditional device manufacturing. The company's current market capitalization stands at $4.50B, supported by annual revenue of $2.35B and an employee base of 2,442 individuals. These valuation and revenue figures indicate that the company has established a significant foothold as a mid-to-large-cap entity within the specialty healthcare landscape, commanding a substantial market presence that reflects both consumer demand and the scale of its distribution network across multiple jurisdictions.
재무 건전성
The company reported total revenue of $2.35B over the trailing twelve months, generating a net income of $128.37M and an EBITDA of $175.66M during the same period. The substantial gap between the $2.35B in revenue and the $128.37M in net income reveals a high-cost structure where operating expenses consume a significant portion of top-line growth, resulting in a relatively thin bottom line despite strong sales volume. The firm generated $110.51M in free cash flow, which provides a critical measure of financial flexibility allowing the company to fund operations, invest in technology, or pursue strategic acquisitions without relying solely on external financing. Analyzing the margins shows a gross margin of 73.8%, indicating high efficiency in producing or sourcing goods relative to sales prices, while an operating margin of 2.7% and a profit margin of 5.5% suggest that administrative and selling expenses are substantial relative to the revenue base. The balance sheet compares $577.49M in cash against $1.12B in total debt, resulting in a debt-to-equity ratio of 207.16, which indicates a highly leveraged capital structure where debt obligations significantly exceed equity capitalization. Liquidity is supported by a current ratio of 1.90, suggesting the company holds sufficient current assets to cover its short-term liabilities nearly twice over. Return on equity stands at 25.2% while return on assets is 5.3%, revealing that management is generating high returns on shareholders' invested capital but that the overall asset base requires significant leverage to achieve such equity returns.
밸류에이션 평가
The stock carries a trailing P/E ratio of 38.73 compared to a forward P/E of 13.91, implying that the market is currently pricing in a significant expected improvement in future earnings relative to historical performance. The price-to-book ratio is 8.30, which indicates that the market values the company at a substantial premium over its net book value, reflecting intangible assets such as brand equity and proprietary technology that are not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 1.92 and an EV/EBITDA of 28.72, suggesting that investors are willing to pay a high multiple for sales and earnings given the anticipated growth trajectory of the business model. The stock's recent trading range spans a 52-week high of $70.43 and a 52-week low of $13.74, illustrating extreme price volatility over the past year. The beta value of 2.31 indicates that the stock's price is expected to be significantly more volatile than the broader market, moving with greater magnitude during periods of market stress or rally.
Growth & Income
Revenue growth over the last year stands at 28.4%, whereas earnings growth is negative at -17.4%, indicating that profitability is lagging behind sales expansion, likely due to the high operating expenses mentioned in the financial health analysis. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm retains all of its earnings to fund operations and growth initiatives rather than distributing cash to shareholders. This reinvestment strategy is consistent with companies in high-growth phases that prioritize expanding their market share and developing new product lines over providing immediate income to investors. Consequently, the overall growth and income profile is characterized by aggressive top-line expansion coupled with current profitability challenges and a complete absence of dividend income, relying entirely on capital appreciation potential driven by future earnings recovery.